The relative immunogenicity of 20-valent and 15-valent pneumococcal conjugate vaccines: A systematic review and network meta-analysis.

Hum Vaccin ImmunotherJul 20, 2026 (epub)
Clinical ResearchInfectious DiseasesPreventive Medicine / Public HealthOpen access

Ilaria Valentini, Erika Alessandra Strangi, Gaia Baccarini et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the immunogenicity of 20-valent (PCV20) versus 15-valent (PCV15) pneumococcal conjugate vaccines in adults. The analysis included 17 trials, with nine providing opsonophagocytic activity (OPA) data. PCV20 showed comparable or lower OPA responses than PCV15 for most serotypes, with PCV15 demonstrating significantly higher responses for several serotypes, including serotype 3.

Key findings

  • PCV20 elicited comparable or lower OPA responses than PCV15 for most serotypes.
  • PCV15 showed significantly higher OPA responses for several serotypes, including serotype 3.
  • PCV20 exceeded PCV15 only for serotype 4.
  • Age-stratified results indicated greater advantages for PCV15 in older adults.

Why it matters

Understanding the relative immunogenicity of pneumococcal vaccines is crucial for optimizing vaccination strategies in adults, particularly in older populations who may be at higher risk for pneumococcal disease.

Source

PubMed · PMID 42477963Free full text on PubMed Central

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.